Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems;Inactivation virale par procédé solvant-détergent de minipools de plasma, de cryoprécipité et de surnageant de cryoprécipité dans des dispositifs à usage unique

Transfusion Clinique et Biologique

Volumn 15, Issue 3, 2008, Pages 129-134

  Burnouf, T ^a   Goubran, H A ^b   Radosevich, M ^a   El Ekiaby, M ^c  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b Faculty of Medicine   (Egypt)

^c Shabrawishi Hospital Blood Bank   (Egypt)

Author keywords

Cryo poor plasma; Cryoprecipitate; Disposables; Minipool; Plasma; Solvent detergent; Virus

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 8; DETERGENT; FIBRINOGEN; PLASMA PROTEIN; SOLVENT;

ARTICLE; BLOOD BANK; BOVINE DIARRHEA VIRUS; CRYOPRECIPITATE; HUMAN IMMUNODEFICIENCY VIRUS; PLASMA TRANSFUSION; PSEUDORABIES HERPETOVIRUS; VALIDATION PROCESS; VIRUS INACTIVATION;

BLOOD PRESERVATION; BLOOD PROTEINS; BLOOD TRANSFUSION; CRYOPRESERVATION; DETERGENTS; HUMANS; PLASMA; PRECIPITATION; QUALITY ASSURANCE, HEALTH CARE; SOLVENTS; VALIDATION STUDIES AS TOPIC; VIRUS INACTIVATION;

EID: 47749141093     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2008.04.007     Document Type: Article

References (36)

1. Horowitz B., Wiebe M.E., Lippin A., and Stryker M.H. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(N-butyl)phosphate detergent combinations. Transfusion 25 (1985) 516-522
2. Burnouf T. Modern plasma fractionation. Transfus Med Rev 21 (2007) 101-117
3. Burnouf T., and Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 14 (2000) 94-110
4. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of Hepatitis B and C viruses and HIV type 1. Transfusion 39 (1999) 1160-1168
5. WHO: guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. http://www.who.int/ Geneva; 2003.
6. Burnouf T. Chromatography in plasma fractionation: benefits and future trends. J Chromatogr B Biomed Appl 664 (1995) 3-15
7. Horowitz B., Bonomo R., Prince A.M., Chin S.N., Brotman B., and Shulman R.W. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
8. Solheim B.G., Rollag H., Svennevig J.L., Arafa O., Fosse E., and Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 40 (2000) 84-90
9. Piet M.P., Chin S., Prince A.M., Brotman B., Cundell A.M., and Horowitz B. The use of tri(N-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 30 (1990) 591-598
10. Horowitz B., Lazo A., Grossberg H., Page G., Lippin A., and Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74 Suppl. 1 (1998) 203-206
11. Piquet Y., Janvier G., Selosse P., Doutremepuich C., Jouneau J., Nicolle G., et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63 (1992) 251-256
12. Hellstern P., Sachse H., Schwinn H., and Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63 (1992) 178-185
13. Mast A.E., Stadanlick J.E., Lockett J.M., and Dietzen D.J. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 94 (1999) 3922-3927
14. Beeck H., and Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74 Suppl. 1 (1998) 219-223
15. de Jonge J., Groenland T.H., Metselaar H.J.J.N., van Vliet I.J., Visser H.H., and Tilanus HW L. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 94 (2002) 1127-1131
16. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
17. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., and Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
18. Harrison C.N., Lawrie A.S., Iqbal A., Hunter A., and Machin S.J. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 94 (1996) 756-758
19. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 46 (2006) 2100-2108
20. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 91 (2006) 56-62
21. Horowitz B., Prince A.M., Horowitz M.S., and Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand 81 (1993) 147-161
22. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals 35 (2007) 349-353
23. Burnouf T., Caron C., Goubran H.A., Radosevich M., Goudemand J., and El-Ekiaby M. An improved, concentrated, mini-pool solvent-detergent treated cryoprecipitate prepared using a newly-developed single-use bag processing system. Int Soc Blood Transfus (2008)
24. Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M, Production and properties of a concentrated mini-pool solvent-detergent treated cryoprecipitate prepared in a single-use bag system. Haemophilia. Soumis à publication.
25. Burnouf-Radosevich M., Burnouf T., and Huart J.J. Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sang 58 (1990) 77-84
26. Burnouf T., Burnouf-Radosevich M., Huart J.J., and Goudemand M. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 60 (1991) 8-15
27. Burnouf-Radosevich M., and Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 62 (1992) 1-11
28. CPMP: EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines. http://www.emea.eu.int. Biologicals. 1991;19:247-51.
29. CPMP: Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (revised). CPMP/BWP/CPMP/5136/03. http://www.emea.eu.int. London: European Agency for the Evaluation of Medicinal Products (EMEA); 1996.
30. Bryant B.J., and Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 131 (2007) 719-733
31. Hornsey V.S., Drummond O., Young D., Docherty A., and Prowse C.V. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 11 (2001) 31-36
32. Heger A., Romisch J., and Svae T.E. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apheresis Sci 35 (2006) 223-233
33. Seghatchian J., and Krailadsiri P. What's happening? The quality of methylene blue treated FFP and cryo. Transfus Apheresis Sci 25 (2001) 227-231
34. Aznar J.A., Molina R., and Montoro J.M. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39 (1999) 748-750
35. Singh Y., Sawyer L.S., Pinkoski L.S., Dupuis K.W., Hsu J.C., Lin L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46 (2006) 1168-1177
36. Larrea L., Calabuig M., Rivera J., Vicente V., and Roig R. Influence of riboflavin photoinactivation treatment of coagulation factors from fresh frozen plasma. 3B-S07-4. Vox Sang 93 (2007) 19-20